Last quarter (Q4 2023), Mind Medicine's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Mind Medicine's net income was $-23.86M. See Mind Medicine’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	-	-	-	-	-
Cost of Revenue	-	-	-	-	$ 3.84M
Gross Profit	-	-	-	-	$ -3.84M
Operating Expense	$ 44.99M	$ 93.92M	$ 66.33M	$ 93.85M	$ 33.03M
Operating Income	$ -44.99M	$ -93.92M	$ -66.33M	$ -93.85M	$ -33.03M
Net Non Operating Interest Income Expense	$ 2.09M	$ 4.66M	$ 1.50M	$ -359.00K	$ -164.00K
Other Income Expense	$ -535.33K	$ 6.64M	$ -7.84M	$ -106.00K	$ 873.00K
Pretax Income	$ -42.37M	$ -95.73M	$ -56.80M	$ -94.19M	$ -34.20M
Tax Provision	$ -6.63K	-	-	$ -1.16M	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -42.36M	$ -95.73M	$ -56.80M	$ -93.04M	$ -34.20M
Basic EPS	$ -1.80	$ -2.44	$ -1.84	$ -0.23	$ -1.95
Diluted EPS	$ -1.80	$ -2.44	$ -1.84	$ -0.23	$ -1.95
Basic Average Shares	$ 118.55M	$ 39.16M	$ 30.86M	$ 410.66M	$ 17.75M
Diluted Average Shares	$ 118.55M	$ 39.16M	$ 30.86M	$ 410.66M	$ 17.75M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 44.99M	$ 93.92M	$ 66.33M	-	-
Net Income From Continuing And Discontinued Operation	$ -42.36M	$ -95.73M	$ -56.80M	$ -93.04M	$ -34.20M
Normalized Income	$ -31.30M	$ -70.36M	$ -41.75M	$ -95.35M	$ -25.13M
Interest Expense	-	-	-	-	-
EBIT	$ -42.37M	$ -95.73M	$ -56.80M	$ -93.83M	$ -34.03M
EBITDA	$ -40.77M	$ -92.57M	$ -53.62M	$ -91.22M	$ -34.03M

Currency in USD

Mind Medicine Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing